Performance Wealth Partners LLC Takes Position in DexCom, Inc. $DXCM

Performance Wealth Partners LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 25,838 shares of the medical device company’s stock, valued at approximately $1,740,000.

Other large investors have also recently bought and sold shares of the company. Reflection Asset Management acquired a new position in shares of DexCom during the 4th quarter worth about $25,000. Ascentis Independent Advisors acquired a new stake in shares of DexCom during the 1st quarter worth about $25,000. MCF Advisors LLC acquired a new stake in shares of DexCom during the 4th quarter worth about $32,000. Wellington Grp LLC lifted its stake in DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after purchasing an additional 475 shares during the last quarter. Finally, DV Equities LLC acquired a new position in DexCom in the fourth quarter valued at approximately $36,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

DXCM has been the topic of several research analyst reports. Mizuho lifted their price target on shares of DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Truist Financial set a $93.00 target price on DexCom and gave the stock a “buy” rating in a research report on Friday, July 31st. Robert W. Baird set a $105.00 target price on DexCom in a report on Friday, July 31st. Canaccord Genuity Group set a $90.00 target price on DexCom and gave the company a “buy” rating in a research report on Monday, August 3rd. Finally, BTIG Research restated a “buy” rating and set a $90.00 price target (up from $80.00) on shares of DexCom in a research note on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $88.71.

Insider Buying and Selling at DexCom

In other DexCom news, Director Mark G. Foletta sold 2,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the sale, the director owned 48,852 shares of the company’s stock, valued at $4,168,052.64. This represents a 3.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares of the company’s stock, valued at $8,034,969.15. The trade was a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 99,794 shares of company stock valued at $7,373,321 in the last quarter. Insiders own 0.28% of the company’s stock.

DexCom Trading Down 1.1%

NASDAQ:DXCM opened at $88.76 on Tuesday. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The stock’s 50 day simple moving average is $76.32 and its 200-day simple moving average is $70.44. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $91.96. The firm has a market cap of $33.49 billion, a P/E ratio of 35.08, a PEG ratio of 1.51 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. DexCom’s revenue was up 13.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.48 EPS. Equities analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.